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Abstract
Background: The phytocannabinoid cannabidiol (CBD) exhibits antioxidant and antiinflammatory properties. The
present study was designed to explore its effects in a mouse model of sepsis-related encephalitis by intravenous
administration of lipopolysaccharide (LPS).
Methods: Vascular responses of pial vessels were analyzed by intravital microscopy and inflammatory parameters
measured by qRT-PCR.
Results: CBD prevented LPS-induced arteriolar and venular vasodilation as well as leukocyte margination. In
addition, CBD abolished LPS-induced increases in tumor necrosis factor-alpha and cyclooxygenase-2 expression as
measured by quantitative real time PCR. The expression of the inducible-nitric oxide synthase was also reduced by
CBD. Finally, preservation of Blood Brain Barrier integrity was also associated to the treatment with CBD.
Conclusions: These data highlight the antiinflammatory and vascular-stabilizing effects of CBD in endotoxic shock
and suggest a possible beneficial effect of this natural cannabinoid.
Background
Endotoxic shock (ES) is a life-threatening condition with
mortality rates of 40-70% that usually takes place in ser-
iously ill, immunologically compromised patients [1]. In
ES, usually secondary to Gram-negative bacterial infec-
tion, there is a severe impairment of vascular, coagulant,
immune and inflammatory responses of the host [2].
The lipopolysaccharide (LPS), a component of the cell
wall of gram-negative bacteria, mediates many of the
alterations leading to ES. LPS profoundly impairs
endothelial functions, promoting intravascular coagula-
tion, disruption of the endothelial wall and intense vaso-
dilation and hypotension. The therapeutic usefulness of
potent antiinflammatory agents as steroids remains con-
troversial [2]. Thus, the search for effective treatments
in ES is still demanding.
Encephalopathy is a common complication in ES
patients, usually appearing very early in the pathologic
process and determining the prognosis [3]. LPS injection,
by inducing both endothelial and astrocytic cell dysfunc-
tion [4,5], is particularly harmful for brain circulation,
impairing cerebrovascular autoregulation [3,6]. Autoregu-
latory responses of brain arteries and arterioles guarantee
a constant cerebral perfusion during systemic blood pres-
sure changes, being dependent on a normal endothelial
function, in particular during hypotension [7]. LPS also
disrupts the coupling of local cerebral blood flow (CBF)
with the activity of underlying neurons [3,4].
Cannabidiol (CBD] is a phytocannabinoid with well-
known antiinflammatory and antioxidant properties
[8,9]. El-Remessy et al [10] recently reported that CBD
prevented inflammatory and oxidative damage and pre-
served endothelial integrity in an experimental model of
diabetic retinopathy. Furthermore, CBD preserves cere-
bral circulation in pathological conditions such as brain
ischemia [11]. Recent data support the clinical use of
CBD for the treatment of a variety of damaging
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myopathy. In particular, the antioxidant properties of
CBD seem to play a major role in the protective effects
of this phytocannabinoid against the oxidative and nitro-
sative stress induced by chemoterapy agents and by high
glucose conditions [12,13].
In the present work, we aimed to test the beneficial
effects of CBD in brain circulation and inflammation in
an in vivo model of sepsis after parenteral injection of
LPS. To that end, we opened a cranial window in adult
mice to study vascular responses by intravital micro-
scopy. Former studies using this method have demon-
strated that topic application of LPS altered arteriolar
responses [14]; however, few studies have so far
reported on the effect of i.v. injection of LPS. Such a dif-
ference is relevant as LPS cannot readily cross the blood
brain barrier (BBB) [15] and because, during the actual
septic condition, both endotoxin release and leukocyte
activation take place inside the intravascular space [16].
Methods
Mice and preparation for intravital microscopy
Adult C57BL/6J mice were maintained in a temperature-
controlled specific pathogen-free facility with a strict
12-hour light/dark cycle and with free access to food and
water. All experiments were performed in accordance to
international and local guidelines as approved by an inter-
nal committee (86/609/EEC). Mice were anesthetized with
ketamine plus medetomidine (50 mg/kg and 1 mg/kg,
respectively). After removing the skin and muscle, a cus-
tom-made device was attached to the cranial surface and
then fitted to the microscope. Body temperature was con-
tinuously monitored by a rectal probe and maintained con-
stant with a thermal blanket. Blood pressure (BP) was
monitored by a cuff tail device with a photoelectric sensor
(NIPREM 645, Cibertec, Madrid, Spain). A cranial window
(2 mm of diameter) was then opened with a high-speed
drill, to gain direct access to the brain parenchyma. The tis-
sue was kept humid constantly by subsequent additions of
200 μl-drops of 0.9% saline. Staining of superficial endothe-
lium and microglia was performed by topical administra-
tion of Griffonia simplicifolia conjugated with fluorescein
(Vector Laboratories, Burlingame, CA, USA), in a 0.9%
NaCl solution, for 30 min. At the beginning of the experi-
ment, at 90 and at 180 min, a 50 μL blood sample was
obtained by tail puncture to determine blood gases
(i-STAT, Abbot Laboratories, NJ, USA). At the end of the
experiment mice were killed by decapitation and brains
harvested, frozen and conserved at -80°C until use.
Drug administration
To clearly observe the cerebrovascular tree throughout
the entire experiment, 100 μl of a 70000 MW Texas red-
conjugated dextrane solution (Invitrogen, Carlsbad, CA,
USA) was administered through the tail vein. This
approach stains blood plasma while leaving nucleated
cells unstained [17]. Afterwards, vehicle (Tween/saline,
N = 7), LPS (Sigma, St Louis, MO, USA; 1 mg/kg, N = 8),
LPS+CBD (1 mg/kg + 3 mg/kg respectively; Tocris
Bioscience, Bristol, UK, N = 7) or CBD alone (3 mg/kg,
n = 5) were administered i.v. through the tail vein in a
total volume of 100 μl. Doses of LPS and CBD were cho-
sen based on previous data [5,18]. A single dose of CBD
was chosen because its long half-life time [18] makes it
appropriate for experiments lasting for 3 h as ours.
Image acquisition and analysis
Observations were made using a Nikon 90i upright
microscope coupled to a C1 scanhead confocal system
with two laser sources (Arg 488 nm and He/Ne
543 nm). Once the area of interest was defined, 60 μm-
thick stacks in the Z-axis (3 μm steps) were obtained with
the Nikon EZ-C1 software, every 15 min for a total time
of 180 min post drug administration. Three-dimensional
constructs were analyzed and changes in the diameter of
venules (internal diameter 39-112 μm) and third-order
arterioles (internal diameter 14-50 μm) (at least 4 of each
per animal) measured. Pial vessels of those diameters are
considered as optimal for intravital studies on microvessel
reactivity [19]. In addition, the total number of marginated
cells (revealed as immobilized black dots inside the vessels)
at each time point was counted and the accumulated
amount was expressed per area unit (μm
2). To that end,
the total area corresponding to vessels was estimated in
each field of observation by means of ImageJ (NIH)
software.
BBB integrity
70000 MW dextrane is unable to leave the blood vessels
under normal conditions, but diffuses into the brain
parenchyma when BBB integrity is compromised. In
order to measure this phenomenon, laser-scanning
micrographs were analyzed and fluorescence intensity
across a cross-section of edematous vessels was mea-
sured. This allowed the analysis of fluorochrome distri-
bution inside and outside the affected vessels as an
index of BBB damage [20].
Quantification of markers of oxidative stress
Concentrations of 4-hydroxynonenal (HNE) and of mal-
ondialdehyde (MDA) as markers of oxidative stress,
were measured in frozen brain tissue by ELISA (OxiSe-
lect HNE-His Adduct and OxiSelect MDA Adduct, Cell
Biolabs, San Diego, CA, USA).
COX-2, TNF-a and iNOS mRNA levels
mRNA levels of cyclooxygenase (COX)-2, tumor necro-
sis factor-alpha (TNF-a)a n di n d u c i b l en i t r i co x i d e
Ruiz-Valdepeñas et al. Journal of Neuroinflammation 2011, 8:5
http://www.jneuroinflammation.com/content/8/1/5
Page 2 of 9synthase (iNOS) were quantified by qRT-PCR from fro-
zen midbrains. Total RNA was extracted using the Tri-
pure Isolation Reagent (Roche Diagnostics, Mannheim,
Germany). Single-stranded complementary DNA (cDNA)
was synthesized from 1 μg of total RNA using the Tran-
scriptor First Strand cDNA Synthesis Kit (Roche Diag-
nostics, Mannheim, Germany). PCR primers and
TaqMan probes were designed by Tib Molbiol (Berlin,
Germany) as shown in table 1. For normalization, 18S
primers and probe number 55 from Universal ProbeLi-
brary probes 1-165 (Roche) were utilized. Gene expres-
sion was quantified using the Quantimix Easy Probes kit
(Biotools, Madrid, Spain) in concert with a LightCycler
thermocycler (Roche). Standard curves were calculated
for quantification purposes using ten-fold serial dilutions
of cDNA from brain mouse. The transcript amounts
were calculated using the second derivate maximum
mode of the LC-sotfware version 4.0. The specific tran-
script quantities were normalized to the transcript
amounts of the reference gene 18S. All further calcula-
tions and statistical analyses were carried out with these
values referred to as relative expression ratios.
Statistical analysis
Results are expressed as mean ± SEM of the indicated
number of experiments. Changes in vessel diameter with
time were compared between groups by 2-way ANOVA.
Differences between groups in enzyme or protein
expression were studied by 1-way ANOVA. Newman-
Keuls post-hoc test was used for multiple comparisons.
A p value of less than 0.05 was considered as statistically
significant. Statistical analysis was performed using the
11.0.0 version of SPSS software (SPSS Inc.).
Results
Physiological data
Mice rectal temperature (37.5 ± 0.6, 37.7 ± 0.2 and
38.1 ± 0.4°C for VEH, LPS, and LPS+CBD, respectively,
NS) measured in the first 30 min of the experiment
indicated a mean decrease of 2°C, remaining stable then.
There were no differences between groups throughout
the experiment.
BP remained stable throughout the entire experiment
and showed no differences between groups (mean
BP [range]: 137 ± 14 [128-150], 141 ± 12 [123-154] and
149 ± 5 [130-155] mmHg for VEH, LPS and LPS+CBD,
respectively, NS).
Blood gas values remained in the normal range until
the end of the experiment, with no differences between
groups (pH: 7.38 ± 0.01, 7.35 ± 0.02 and 7.39 ± 0.04;
pO2: 47.7 ± 4.8, 45.6 ± 5.1 and 45.6 ± 2.7 mmHg; and
pCO2: 66.3 ± 9.3, 71.4 ± 8.8 and 61.6 ± 6.3 mmHg, for
VEH, LPS and LPS+CBD, respectively, NS).
CBD counteracts LPS-induced vasodilation
LPS-induced sepsis-associated changes in cerebral blood
flow are due to, among other factors, an excessive vaso-
dilation [21]. As expected, LPS induced a sustained
arteriolar vasodilation of up to 30 ± 3%, starting at t15
min and peaking at t75 min (Figure 1); LPS also induced
a venular vasodilation of up to 15 ± 2% starting at t75.
CBD blunted the vasodilator effect of LPS, so that in
LPS+CBD arteriolar and venular dilation accounted only
for 10 ± 2% and 5 ± 2%, respectively (2-way ANOVA
p < 0.05 vs. LPS, F = 3.48 and F = 4.22 for venules and
arterioles, respectively).
CBD decreases LPS-induced cell margination
To study leukocyte margination and diapedesis, of
paramount importance in LPS-induced sepsis, the intra-
vascular space was stained with 70000 MW Texas
red-conjugated dextrane. Blood cells thus appear as
“ghosts” inside the vessels [17]. With this approach, only
cells that are stationary or dramatically slowed by adhe-
sive interactions with the vessel wall can be detected
[17,22]. The great majority of these unstained cells are
leukocytes, as they exceed in high number other
nucleated cell types [17]. Leukocyte margination was
not observed in VEH at any time studied, whereas in
LPS-treated animals the density of marginated leuko-
cytes was significantly elevated. LPS+CBD blunted this
effect (Figure 2) (2-way ANOVA p < 0.05, F = 1.87).
LPS treatment compromised BBB integrity, and this effect
was prevented by CBD
Mice receiving LPS showed a clear disruption of the
BBB, as revealed by extravasation of the fluorescently-
labelled dextrane starting 45 min after administration
Table 1 Sequences for primers and probes employed in
this study
GENES PRIMER/
PROBE
SEQUENCES FOR PRIMERS AND PROBES
18S sense AAATCAGTTATGGTTCCTTTGGTC
antisense GCTCTAGAATTACCACAGTTATCCAA
Probe #55 Use universal ProbeLibrary, Roche Applied
Science
iNOS sense GCTCCTCCCAGGACCACA
antisense GCTGGAAGCCACTGACACTT
Probe
TaqMan
6FAM-CACCTACCGCACCCGAGATGG–BBQ
COX-2 sense TGACCCACTTCAAGGGAGTCT
antisense CTGTCAATCAAATATGATCTGGATGTC
Probe
TaqMan
6FAM-AACAACATCCCCTTCCTGCGAAGTT–BBQ
TNF-a sense GCCTATGTCTCAGCCTCTTCTCATT
antisense CCACTTGGTGGTTTGCTACGA
Probe
TaqMan
6FAM-CCATAGAACTGATGAGAGGGAGGCCATTT-
BBQ
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employed for the quantification of BBB integrity [20]. In
animals showing BBB alterations, CBD treatment dra-
matically reduced the extent of dextrane extravasation
(p < 0.05 by 2-way ANOVA, F = 2.23) (Figure 3). Inter-
estingly, no vehicle-treated animals showed significant
changes in BBB integrity.
CBD does not modify HNE or MDA concentrations
No differences were observed between groups in the con-
centration of HNE (1.37 ± 0.4, 1.15 ± 0.3 and 1.39 ± 0.5
μg/ml, for VEH, LPS and LPS+CBD, respectively, NS) or
MDA (3.2 ± 0.3, 2.9 ± 0.4 and 3.3 ± 0.5 μg/ml, for VEH,
LPS and LPS+CBD, respectively, NS) in brain tissue.
CBD reduces LPS-induced expression of COX-2, TNF-a,
and iNOS
LPS triggers a massive inflammatory response involving
cellular mediators such as cytokines and prostaglandins
[21]. Thus, we aimed to quantify the expression of one
crucial cytokine (TNF-a) and of some key enzymes
(COX-2 and iNOS). Taken together, our results confirm
the development of a proinflammatory environment in
LPS-treated mice brain, with increases in mRNA levels
for TNF-a and COX-2 (Figure 4). iNOS expression was
not modified in LPS vs vehicles although CBD-treated
mice exhibited significantly lower expression of this
enzyme. LPS-induced increases of TNF-a and COX-2
were dramatically reduced by CBD (Figure 4).
A
B
†
†
Figure 1 CBD prevented LPS-induced vasodilation. (A) Representative 60 μm Z-stacks of subpial vessels in the mouse brain reflect the
increase in blood vessel diameter after LPS administration (t = 0, left; t = 120 min, right). X-Y labels represent diameter in micrometers. Vascular
tree is evidenced by i.v. administration of 70000 MW Texas red-conjugated dextrane and endothelial and microglial cells were labelled with
topical fluorescein-conjugated Griffonia simplicifolia (green). (B) Treatment with CBD (triangles) significantly decreased the LPS-induced changes
(black circles) in venules (left) and arterioles (right), as compared to vehicle treated animals (open circles). Error bars represent mean ± SEM of
7-8 experiments. †p < 0.05 by 2-way ANOVA. Scale bar: 250 μm.
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CBD alone were observed in any of the aforementioned
determinations.
Discussion
CBD is a natural cannabinoid lacking psychotropic
effects. This fact, together with its well-known antiin-
flammatory, antioxidant and neuroprotective effects, has
focused research on its possible therapeutic relevance
[8,23]. We here report that CBD counteracts some of
the inflammatory responses associated to LPS in the
mouse brain.
In the present work we observed that parenterally-
introduced LPS induced dramatic arteriolar dilation,
starting as early as 30 min after i.v. injection. Previous
in vivo experiments on the effect of parenteral or intra-
cerebral LPS administration (1 mg/kg or more) on brain
circulation in rodents measured local or global CBF
[3,6,15]. In those studies, brain hyperemia took place
1 h after LPS administration. We did not directly
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Figure 2 CBD inhibited leukocyte margination. (A) Representative 60 μm Z-stacks of subpial vessels at t = 0 (left) and t = 120 min (right)
after LPS administration. Note the intense accumulation of nucleated cells in the luminal side of blood vessels at t = 120 min, detectable as
static black dots (arrows). (B) Quantification of CBD effect on cell margination (expressed as immobilized cells/μm
2), reflecting a dramatic
inhibition of the process by this cannabinoid over the experimental time course. Vehicle (open circles), LPS (black circles) and LPS+CBD
(triangles). Error bars represent mean ± SEM of 7-8 experiments.
†p < 0.05 by 2-way ANOVA. Scale bar: 250 μm.
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venular diameter after LPS administration likely
reflected an increase in CBF as, due to the poor reactiv-
ity of the cerebral venous myocytes, brain venule dia-
meter is mostly dependent on CBF [19]. Brain
hyperemia after abnormal brain vasodilation represents
al a c ko fa u t o r e g u l a t i o n ,d u e to endothelial and glial
dysfunction [3]. Administration of CBD blunted the
arteriolar dilation, so arteriolar diameter remained simi-
lar to control throughout the experiment. Besides, venu-
lar diameter after CBD administration remained similar
to control. Altogether, these results suggest that in the
presence of CBD, CBF remained similar to control.
On the other hand, the compromise of BBB integrity
is a common feature of LPS-associated encephalitis and
may be caused by the disruption of endothelial tight
junctions mainly by the action of several cytokines.
Increased BBB permeability leads to secondary lesions
that worsen with increased duration of septic shock and
correlate with poor outcome [16]. CBD reduced BBB
alteration, in agreement with a recent report showing
that CBD prevents endothelial cell inflammatory
responses and preserves barrier functions in a murine
model of experimental diabetes [24]. Furthermore, our
data showing that CBD was able to prevent cellular
margination match with recent observations in vivo in
which CBD decreased the expression of adhesion mole-
c u l e sa sw e l la sc h e m o t a x i si ne x p e r i m e n t a lm o d e l so f
inflammation and tissue injury [12,13].
LPS is known to induce COX-2 in neurons and glial
cells, subsequently increasing COX metabolites of ara-
chidonic acid, which contributes to LPS-induced
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Figure 3 CBD prevented LPS-induced extravasation, as an index of BBB integrity. (A) Representative laser-scanning micrographs of
microvasculature at t = 90 (left), t = 105 (center) and t = 120 min (right) after LPS administration. Note the increasing red signal outside the
vessel, indicating extravasation of the high molecular weight, fluorescent dextrane, confirmed by the measurement of fluorescence intensity
across a cross-section (white line) at each time point. (B) Representation of the variation with time of the extravasation as measured by
fluorescence intensity in the extravascular portion, in LPS (black circles) and LPS+CBD (triangles) treated animals, as compared to vehicle (open
circles). Error bars represent mean ± SEM of 7-8 experiments.
†p < 0.05 by 2-way ANOVA. Scale bar: 200 μm.
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inhibits COX-2 activity [18], an effect dependent on the
cell type, as it is not observed in tumoral cells [25]. Our
results confirm previous observations by Costa et al [26]
showing that oral administration of CBD diminishes car-
rageenan-induced paw inflammation in rat by decreasing
COX activity and edema formation.
Since hemodynamic changes in ES are triggered by the
massive inflammatory reaction induced by LPS as well
as by the increased oxidative stress, CBD beneficial
effects could also derive both from its antiinflammatory
and antioxidant properties [27]. Binding of LPS to speci-
fic receptors in brain endothelial cells triggers a series of
signaling events leading to the increase of cytokine pro-
duction [28]. These cytokines participate in the disrup-
tion of BBB integrity and induce brain vessel dilation
[21,29]. TNF-a is a major mediator in septic encephalo-
pathy, as mice deficient in TNF-receptor 1 are more
resistant to LPS-induced changes [30]. CBD exerts a
potent immunosuppressive effect in vivo,r e d u c i n gp r o -
duction of TNF-a and other cytokines from immune
cells [8,12,13,18].
LPS is one the most important stimuli for the induc-
tion of iNOS in brain cells [15]. iNOS induction leads
to massive NO production, inducing endothelial cyto-
toxicity by direct damage and by increasing oxidative
stress and inflammation [31], and impairing cerebrovas-
cular autoregulation [3]. However, due to the limited
ability of LPS to cross the BBB, the effect of parenteral
LPS on brain iNOS mRNA levels could not be observed
before 6 h after injection [5]. In agreement, we did not
find an increase of iNOS expression in brain during our
3 h period of study after LPS injection. Thus, the CBD-
induced decrease of iNOS expression likely corre-
sponded with the prevention by CBD of iNOS induction
in brain due to the experimental procedure. A similar
effect on iNOS induction has been described for CBD
newborn mice brains after manipulation to perform oxy-
gen-glucose deprivation of forebrain slices [32]. CBD is
known to prevent iNOS expression through inhibition
of MAPK and NF-B signaling [12,13,33,34], an obser-
vation that may be especially relevant in advanced stages
of circulatory shock, when iNOS contribution to NO
production seems to be maximal [35]. Remarkably, per-
oxynitrite formation (known to participate in pathophy-
siological alterations of shock) has been found to follow
a similar time course to iNOS expression after challenge
with LPS in rats (reviewed in 35).
We did not observe any difference between groups in
brain concentration of oxidative stress markers as HNE
or MDA. LPS administration leads to a brief transient
increase of oxidative stress markers in brain, observed
shortly after injection [36]. Nevertheless, the sustained
and significant increase of these markers is observed 6 h
after LPS administration, thus beyond our experimental
period, and lasts for at least 24 h, being mainly due to
cytokine-induced activation of microglial cells [36].
Finally, the complex pharmacological profile of CBD
may explain some of our data [reviewed in [37]]. Thus,
and although the possible mediation of cannabinoid
receptors has not been analyzed in the present experi-
ments, it is important to note that recent reports sug-
gest that CBD effects on LPS-induced inflammation are
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Figure 4 CBD treatment modifies the pattern of induction of
COX-2 (A), TNF-a (B) and iNOS (C) mRNAs, as measured by
quantitative real time PCR. Error bars represent mean ± SEM of
7-8 experiments. *p < 0.05 vs control. #p < 0.05 vs LPS by ANOVA.
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properties on CB1 receptors might underlie some of the
observed effects, as CB1 receptor blockade prevents the
primary hypotensive response to LPS [27]. Furthermore,
CB1 receptor blockade has been proposed to improve
survival in ES [38]. In addition, CBD might also partially
activate CB2 receptors, which play a crucial role in the
regulation of the immune response against sepsis in an
animal model of cecal ligation and puncture [39].
Furthermore, its activity as a CB2 receptor inverse ago-
nist could partially account for these actions since CB2
receptor inverse agonism reduces clinical signs of
inflammation and cell migration [40]. Finally, CBD may
also alter inflammatory processes by targeting the
abnormal CBD receptor [41], as this receptor partially
mediates the hypotensive effects of anandamide and
other cannabinoids [42,43].
Conclusions
In conclusion, CBD blunted LPS-induced changes in
vessel diameter and permeability as well as leukocyte
margination, effects that were associated with modula-
tion of cytokine and NO production. However, more
studies on the optimal dosage regime, timing of effec-
tiveness and response in other models of sepsis are war-
ranted before considering CBD as a candidate for
treatment in humans.
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